Сонеситатуг ведотин

Prop. INN (наименование, предложенное ВОЗ)

2813237-93-1

immunoglobulin G1-kappa, anti-[Homo sapiens CLDN18 (claudin 18, claudin-18, surfactant associated protein J, SFTPJ) isoform 2], humanized monoclonal antibody, conjugated on an average of four cysteinyl residues to vedotin, comprising a cleavable linker and monomethylauristatin E (MMAE);
H-gamma1 heavy chain humanized (1-448) [VH (Homo sapiens IGHV4-59*11 (94.8%) -(IGHD) -IGHJ4*01 (92.9%), CDR-IMGT [9.7.11] (26-34.52-58.97-107)) (1-118) -Homo sapiens IGHG1*03 (100%) G1m3, nG1m1 CH1 R120, CH3 E12, M14 (CH1 R120 (215) (119-216), hinge 1-15 (217-231), CH2 (232-341), CH3 E12 (357), M14 (359) (342-446), CHS (447-448)) (119-448)], (221-220')-disulfide with L-kappa light chain humanized (1'-220') [V-KAPPA (Homo sapiens IGKV4-1*01 (92.1%) -IGKJ1*01 (100%), CDR-IMGT [12.3.9] (27'-38'.56'-58'.95'-103')) (1'-113') -Homo sapiens IGKC*01 (100%) Km3 A45.1, V101 (C-KAPPA A45.1 (159'), V101 (197')) (114'-220')]; dimer (227-227'':230-230'')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, derived from the cell line CHO-K1, lacking the glutamine synthetase (GS-KO) gene, glycoform alfa; substituted at the sulfur atoms of four l-cysteinyl residues on an average among 221, 227, 230, 220', 221'', 227'', 230'' and 220''' with a group consisting of (3RS)-1-(6-{[(2S)-1-{[(2S)-5-(carbamoylamino)-1-{4-[({[(2S)-1-{[(2S)-1-{[(3R,4S,5S)-1-{(2S)-2-[(1R,2R)-3-{[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]amino}-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl}-3-methoxy-5-methyl-1-oxoheptan-4-yl](methyl)amino}-3-methyl-1-oxobutan-2-yl]amino}-3-methyl-1-oxobutan-2-yl](methyl)carbamoyl}oxy)methyl]anilino}-1-oxopentan-2-yl]amino}-3-methyl-1-oxobutan-2-yl]amino}-6-oxohexyl)-2,5-dioxopyrrolidin-3-yl (vedotin)

Поделиться этой страницей